FDA Brief

Warning letters Drugs

FDA warning letter to

Wild Arabic Herbs

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA warns Wild Arabic Herbs that its website sells Edral-17t as an unapproved drug for prostate and testicular cancers.

What happened

FDA reviewed the company’s website in May 2026 and found product labeling for “Edral-17t” claiming it treats prostate cancer, testicular malignancies, and other cancers. FDA said these claims make the product a drug and that it is a new drug without an approved application.

What FDA found

  1. FDA says the website claims make Edral-17t a drug intended to treat disease.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA says Edral-17t is a new drug—one not generally recognized as safe and effective—and has no FDA-approved application.

    FD&C Act sections 201(p) and 505(a), 21 U.S.C. 321(p) and 355(a)
  3. FDA says selling or shipping this unapproved drug across state lines violates the FD&C Act.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA tells the company to respond in writing within 15 business days to FDAAdvisory@fda.hhs.gov with the steps taken to correct the violations, steps to prevent recurrence, and supporting documents, using reference number 729192.

Who should pay attention

  • sellers of herbal or supplement products with disease claims
  • online platforms hosting product health claims
  • consumers considering herbal cancer treatments

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk